annual EBIT:
$1.56B-$330.95M(-17.54%)Summary
- As of today (July 3, 2025), RPRX annual earnings before interest & taxes is $1.56 billion, with the most recent change of -$330.95 million (-17.54%) on December 31, 2024.
- During the last 3 years, RPRX annual EBIT has risen by +$148.98 million (+10.59%).
- RPRX annual EBIT is now -42.99% below its all-time high of $2.73 billion, reached on December 31, 2019.
Performance
RPRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
$498.69M+$98.58M(+24.64%)Summary
- As of today (July 3, 2025), RPRX quarterly earnings before interest & taxes is $498.69 million, with the most recent change of +$98.58 million (+24.64%) on March 31, 2025.
- Over the past year, RPRX quarterly EBIT has increased by +$458.74 million (+1148.01%).
- RPRX quarterly EBIT is now -66.97% below its all-time high of $1.51 billion, reached on December 31, 2019.
Performance
RPRX quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
$2.02B+$458.74M(+29.48%)Summary
- As of today (July 3, 2025), RPRX TTM earnings before interest & taxes is $2.02 billion, with the most recent change of +$458.74 million (+29.48%) on March 31, 2025.
- Over the past year, RPRX TTM EBIT has increased by +$643.87 million (+46.96%).
- RPRX TTM EBIT is now -32.03% below its all-time high of $2.96 billion, reached on September 30, 2020.
Performance
RPRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RPRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -17.5% | +1148.0% | +47.0% |
| 3 y3 years | +10.6% | +184.7% | +45.4% |
| 5 y5 years | -43.0% | +206.6% | -28.5% |
RPRX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -17.5% | +272.3% | -42.9% | +188.6% | at high | +382.0% |
| 5 y | 5-year | -43.0% | +272.3% | -42.9% | +188.6% | -32.0% | +382.0% |
| alltime | all time | -43.0% | +272.3% | -67.0% | +188.6% | -32.0% | +382.0% |
RPRX EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $498.69M(+24.6%) | $2.02B(+29.5%) |
| Dec 2024 | $1.56B(-17.5%) | $400.11M(-54.2%) | $1.56B(-19.0%) |
| Sep 2024 | - | $872.86M(+258.6%) | $1.92B(+57.9%) |
| Jun 2024 | - | $243.39M(+509.1%) | $1.22B(-11.3%) |
| Mar 2024 | - | $39.96M(-94.8%) | $1.37B(-27.3%) |
| Dec 2023 | $1.89B(+351.5%) | $764.84M(+355.0%) | $1.89B(+237.4%) |
| Sep 2023 | - | $168.11M(-57.8%) | $559.36M(-15.1%) |
| Jun 2023 | - | $398.29M(-28.4%) | $658.64M(-17.6%) |
| Mar 2023 | - | $556.04M(-198.8%) | $798.92M(+91.1%) |
| Dec 2022 | $418.02M(-70.3%) | -$563.08M(-310.6%) | $418.02M(-61.4%) |
| Sep 2022 | - | $267.39M(-50.4%) | $1.08B(+0.1%) |
| Jun 2022 | - | $538.56M(+207.5%) | $1.08B(-22.0%) |
| Mar 2022 | - | $175.15M(+74.0%) | $1.39B(-1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $1.41B(-24.3%) | $100.64M(-62.2%) | $1.41B(-17.8%) |
| Sep 2021 | - | $266.12M(-68.5%) | $1.71B(-18.5%) |
| Jun 2021 | - | $844.18M(+329.8%) | $2.10B(+11.0%) |
| Mar 2021 | - | $196.39M(-51.4%) | $1.89B(+1.8%) |
| Dec 2020 | $1.86B(-31.9%) | $404.47M(-38.3%) | $1.86B(-37.3%) |
| Sep 2020 | - | $655.70M(+3.1%) | $2.96B(+5.2%) |
| Jun 2020 | - | $636.16M(+291.1%) | $2.82B(+16.0%) |
| Mar 2020 | - | $162.68M(-89.2%) | $2.43B(-11.0%) |
| Dec 2019 | $2.73B(+51.9%) | $1.51B(+196.7%) | $2.73B(+123.7%) |
| Sep 2019 | - | $508.82M(+105.2%) | $1.22B(+71.5%) |
| Jun 2019 | - | $247.94M(-46.5%) | $711.30M(+53.5%) |
| Mar 2019 | - | $463.36M | $463.36M |
| Dec 2018 | $1.80B(+13.0%) | - | - |
| Dec 2017 | $1.59B | - | - |
FAQ
- What is Royalty Pharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for Royalty Pharma?
- What is Royalty Pharma annual EBIT year-on-year change?
- What is Royalty Pharma quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Royalty Pharma?
- What is Royalty Pharma quarterly EBIT year-on-year change?
- What is Royalty Pharma TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Royalty Pharma?
- What is Royalty Pharma TTM EBIT year-on-year change?
What is Royalty Pharma annual earnings before interest & taxes?
The current annual EBIT of RPRX is $1.56B
What is the all time high annual EBIT for Royalty Pharma?
Royalty Pharma all-time high annual earnings before interest & taxes is $2.73B
What is Royalty Pharma annual EBIT year-on-year change?
Over the past year, RPRX annual earnings before interest & taxes has changed by -$330.95M (-17.54%)
What is Royalty Pharma quarterly earnings before interest & taxes?
The current quarterly EBIT of RPRX is $498.69M
What is the all time high quarterly EBIT for Royalty Pharma?
Royalty Pharma all-time high quarterly earnings before interest & taxes is $1.51B
What is Royalty Pharma quarterly EBIT year-on-year change?
Over the past year, RPRX quarterly earnings before interest & taxes has changed by +$458.74M (+1148.01%)
What is Royalty Pharma TTM earnings before interest & taxes?
The current TTM EBIT of RPRX is $2.02B
What is the all time high TTM EBIT for Royalty Pharma?
Royalty Pharma all-time high TTM earnings before interest & taxes is $2.96B
What is Royalty Pharma TTM EBIT year-on-year change?
Over the past year, RPRX TTM earnings before interest & taxes has changed by +$643.87M (+46.96%)